T(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma

被引:82
作者
Garand, R
Avet-Loiseau, H
Accard, F
Moreau, P
Harousseau, JL
Bataille, R
机构
[1] CHU Nantes, Hematol Lab, F-44035 Nantes 01, France
[2] CHU Nantes, Serv Hematol, F-44035 Nantes, France
关键词
multiple myeloma; morphology; cytogenetics;
D O I
10.1038/sj.leu.2403091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent studies have shown that two recurrent translocations, t(4;14)(p16;q32) and t(11;14)(q13;q32), define distinct entities with different prognosis in multiple myeloma (MM). We addressed the issue of whether these illegitimate IGH rearrangements could contribute to the morphological heterogeneity of the malignant plasma cells (PC). Bone marrow aspirates of 178 untreated MM cases with successful molecular cytogenetics analysis using fluorescence in situ hybridization were reviewed. PC of 25/48 (52%) patients with t(11;14) exhibited a lymphoplasmacytoid morphology. Moreover, 25/27 (93%) of the cases with this morphological profile bore the t(11;14). In addition, both cytogenetics and morphological subtypes shared higher incidence of nonsecretory MM. In contrast, 17 out of 28 cases (61%) with t(4;14) exhibited PC with diffuse chromatin pattern. Interestingly, both t(4;14) translocation and immature morphology correlated with higher incidence of high tumor mass and chromosome 13 abnormality. In conclusion, our results suggest that a particular morphology can be the signature of chromosomal abnormalities in MM.
引用
收藏
页码:2032 / 2035
页数:4
相关论文
共 12 条
[1]   Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants [J].
Avet-Loiseau, H ;
Garand, R ;
Lodé, L ;
Harousseau, JL ;
Bataille, R .
BLOOD, 2003, 101 (04) :1570-1571
[2]   Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation [J].
Avet-Loiseau, H ;
Facon, T ;
Grosbois, B ;
Magrangeas, F ;
Rapp, MJ ;
Harousseau, JL ;
Minvielle, S ;
Bataille, R .
BLOOD, 2002, 99 (06) :2185-2191
[3]  
CARTER A, 1987, CANCER, V60, P1060, DOI 10.1002/1097-0142(19870901)60:5<1060::AID-CNCR2820600522>3.0.CO
[4]  
2-3
[5]   Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].
Fonseca, R ;
Blood, E ;
Rue, M ;
Harrington, D ;
Oken, MM ;
Kyle, RA ;
Dewald, GW ;
Van Ness, B ;
Van Wier, SA ;
Henderson, KJ ;
Bailey, RJ ;
Greipp, PR .
BLOOD, 2003, 101 (11) :4569-4575
[6]   Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients [J].
Fonseca, R ;
Blood, EA ;
Oken, MM ;
Kyle, RA ;
Dewald, GW ;
Bailey, RJ ;
Van Wier, SA ;
Henderson, KJ ;
Hoyer, JD ;
Harrington, D ;
Kay, NE ;
Van Ness, B ;
Greipp, PR .
BLOOD, 2002, 99 (10) :3735-3741
[7]   Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology [J].
Goasguen, JE ;
Zandecki, M ;
Mathiot, C ;
Scheiff, JM ;
Bizet, M ;
Ly-Sunnaram, B ;
Grosbois, B ;
Monconduit, M ;
Michaux, JL ;
Facon, T .
LEUKEMIA RESEARCH, 1999, 23 (12) :1133-1140
[8]   Plasmablastic morphology - An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group [J].
Greipp, PR ;
Leong, T ;
Bennett, JM ;
Gaillard, JP ;
Klein, B ;
Stewart, JA ;
Oken, MM ;
Kay, NE ;
Van Ness, B ;
Kyle, RA .
BLOOD, 1998, 91 (07) :2501-2507
[9]  
GREIPP PR, 1985, BLOOD, V65, P305
[10]   The (11;14)(q13;q32) translocation in multiple myeloma - A morphologic and immunohistochemical study [J].
Hoyer, JD ;
Hanson, CA ;
Fonseca, R ;
Greipp, PR ;
Dewald, GW ;
Kurtin, PJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (06) :831-837